Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-11-18 Foreign Filer Report
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2025-11-18 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal declaration by Sanofi regarding 'transactions sur actions propres' (transactions in own shares), specifically detailing share buybacks conducted between November 10, 2025, and November 14, 2025. It includes both an aggregated daily summary and a detailed transaction-by-transaction log, which is standard for share repurchase reporting under market abuse regulations (MAR). This fits the definition of 'Transaction in Own Shares' (POS).
2025-11-17 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and provides a detailed, itemized list of share repurchase transactions conducted by Sanofi between November 10, 2025, and November 14, 2025. It includes specific transaction details such as dates, volumes, prices, and broker information, which aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-11-17 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing a positive opinion from the CHMP (EMA) regarding the approval of a drug (Teizeild). It details the clinical study results, the regulatory status, and provides contact information for investor relations. This is a standard corporate announcement regarding regulatory progress and product development, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like earnings releases or financial reports.
2025-11-14 French
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the approval of a drug (Teizeild). This type of regulatory update, which does not fit into specific financial reporting categories like 10-K or earnings releases, is best classified as a general regulatory announcement.
2025-11-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.